Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dendritic cell-based immunotherapy.

Takuya Osada1, Timothy M Clay, Christopher Y Woo

  • 1Department of Surgery, Program in Molecular Therapeutics, Comprehensive Cancer Center, Duke University Medical Center, Durham, North Carolina 27710, USA.

International Reviews of Immunology
|December 16, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of a STEAP1-Targeted Prostate Cancer Specific Antibody Drug Conjugate Platform with Immunostimulatory Properties.

Research square·2026
Same author

Enhanced efficacy of a next-generation EEEV self-replicating RNA platform for combination cancer immunotherapies.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same author

Vector-directed immunity and boosting capacity of VRP-srRNA anti-tumor vaccines.

NPJ vaccines·2026
Same author

Hemodynamics and Mid-Term Clinical Outcomes Following Valve-in-Valve TAVR With Balloon-Expandable Valves.

Circulation. Cardiovascular interventions·2026
Same author

Inflammation and mutational burden differentially associated with nivolumab or ipilimumab combination efficacy in colorectal cancer.

Nature communications·2025
Same author

Mid-Term Outcomes of Balloon-Expandable Aortic Valve-in-Valve Replacement in the United States.

JACC. Cardiovascular interventions·2025
Same journal

Regulatory T cells in the tumor microenvironment: Mechanisms and clinical implications.

International reviews of immunology·2026
Same journal

Leptin in metabolic-immune crosstalk: Mechanisms of T cell regulation and implications for autoimmune disease therapy.

International reviews of immunology·2026
Same journal

Metabolic alterations in the tumor microenvironment influence the anti-tumor immune function of CD8<sup>+</sup> T cells via epigenetic modifications.

International reviews of immunology·2026
Same journal

Macrophage markers and gene signature profiling reveals mesenchymal stem cells mediated immune modulation in Plasmodium berghei ANKA infection.

International reviews of immunology·2026
Same journal

Natural antigen landscape shaping intestinal Treg cells: Self, diet, and microbiota.

International reviews of immunology·2026
Same journal

Upregulation of ADAM10 reinforces CD8<sup>+</sup> T cells toward exhaustion in the TME.

International reviews of immunology·2026
See all related articles

Dendritic cell (DC) vaccines show promise for cancer immunotherapy by stimulating T-cell responses. Further standardization of protocols and response criteria is needed to confirm their clinical efficacy.

Area of Science:

  • Immunology
  • Oncology
  • Vaccinology

Background:

  • Dendritic cells (DCs) are critical for initiating antigen-specific T-cell responses.
  • DCs are being investigated for active immunotherapy of malignancies.
  • Over a decade of research has provided insights into DC-based vaccine development.

Purpose of the Study:

  • To review developmental insights in dendritic cell (DC)-based cancer vaccines.
  • To identify challenges and future directions for DC vaccine clinical trials.

Main Methods:

  • Review of clinical data and studies on DC-based vaccines.
  • Analysis of factors influencing DC vaccine efficacy, including DC source, antigen loading, maturation, and immunization route.

Main Results:

Related Experiment Videos

  • DC immunization can generate anti-tumor immune responses, with some patients showing favorable clinical responses.
  • Current data is largely inconclusive due to variations in DC preparation, antigen forms, and vaccination protocols.
  • Lack of standardized criteria for defining clinical responses hinders result comparison.

Conclusions:

  • Standardization of clinical and immunological criteria is essential for comparing results across studies.
  • Further research is needed to resolve optimal dosing and clinical settings for DC vaccines.
  • Future trials require standardized approaches to accurately assess the value of DC immunotherapy.